Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting - Liquidia ( NASDAQ:LQDA )
MORRISVILLE, N.C., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral presentations at the CHEST 2025 annual ...
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association ( PHPN ) Symposium - Liquidia ( NASDAQ:LQDA )
MORRISVILLE, N.C., Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation LQDA, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional ...
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association ( PHPN ) Symposium
MORRISVILLE, N.C., Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension ...
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Liquidia Unusual Options Activity - Liquidia ( NASDAQ:LQDA )
High-rolling investors have positioned themselves bullish on Liquidia LQDA, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
MORRISVILLE, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) announced today that members of the company's executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on ...
Liquidia Analysts Raise Their Forecasts Following Q2 Results - Liquidia ( NASDAQ:LQDA )
Liquidia Corporation LQDA reported a loss for the second quarter on Tuesday. The company posted a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents. Sales reached $8.84 million compared to the consensus of $3.86 million.
Liquidia Technologies, Inc. ( LQDA ) Reports Q2 Loss, Beats Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -13.95% and +124.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Is Liquidia Stock Trading Higher On Tuesday? - Liquidia ( NASDAQ:LQDA )
Q2 loss of $0.49 vs. $0.43 estimate; sales surge to $8.84 million after Yutrepia launch. PH-ILD study shows stable tolerability; median walk distance improved by 31.5m. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025.
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
MORRISVILLE, N.C., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, ...
Vericel Corporation ( VCEL ) Reports Q2 Loss, Lags Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +75.00% and -1.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Receives $50 Million from Healthcare Royalty ( HCRx ) Following First Commercial Sale of YUTREPIA™ - Liquidia ( NASDAQ:LQDA )
MORRISVILLE, N.C., June 23, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation LQDA, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing ...
Liquidia Receives $50 Million from Healthcare Royalty ( HCRx ) Following First Commercial Sale of YUTREPIA™
MORRISVILLE, N.C., June 23, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its ...
Insmed Stock Jumps 29% on Encouraging PAH Study Results
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Dow Gains 50 Points; US Small Business Optimism Index Rises In May - Casey's General Stores ( NASDAQ:CASY ) , Calavo Growers ( NASDAQ:CVGW )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday. The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S&P 500 also rose, gaining, 0.29% to 6,023.46. Energy shares jumped by 1.9% on Tuesday.
Liquidia Schedules First Commercial Shipment of YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with PAH and PH-ILD - Liquidia ( NASDAQ:LQDA )
YUTREPIA now available to be prescribed to patients via specialty pharmacies Court denies United Therapeutics' request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch
Liquidia Schedules First Commercial Shipment of YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with PAH and PH-ILD
MORRISVILLE, N.C., June 02, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ ...
These Analysts Boost Their Forecasts On Liquidia - Liquidia ( NASDAQ:LQDA )
On Friday, the U.S. Food and Drug Administration ( FDA ) approved Liquidia Corporation's LQDA Yutrepia ( treprostinil ) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension ( PAH ) and pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) ...
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Liquidia ( NASDAQ:LQDA )
FDA fully approves Yutrepia for PAH and PH-ILD based on positive Phase 3 INSPIRE trial results. Liquidia secured up to $100 million in new financing to support Yutrepia's launch and further clinical trials. Memorial Day Special: Access your full investing command center with trade ideas, ...
U.S. FDA Approves Liquidia's YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with Pulmonary Arterial Hypertension ( PAH ) and Pulmonary Hypertension Associated with Interstitial Lung Disease ( PH-ILD ) - Liquidia ( NASDAQ:LQDA )
FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort Demonstrated tolerability and titratability in the pivotal ...
U.S. FDA Approves Liquidia's YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with Pulmonary Arterial Hypertension ( PAH ) and Pulmonary Hypertension Associated with Interstitial Lung Disease ( PH-ILD )
MORRISVILLE, N.C., May 23, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration ( FDA ) has approved YUTREPIA™ ( ...
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Liquidia ( NASDAQ:LQDA )
New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR's '782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA '782 patent claims same general subject matter as UTHR's invalidated '793 patent
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
MORRISVILLE, N.C., May 12, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation ( UTHR ) filed a complaint on May 9, ...
Liquidia Technologies, Inc. ( LQDA ) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -7.14% and 5.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. ( MRUS ) Reports Q1 Loss, Tops Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -20.69% and 238.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies ( LQDA ) Surges 13.2%: Is This an Indication of Further Gains?
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - Liquidia ( NASDAQ:LQDA )
Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIA FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
MORRISVILLE, N.C., May 02, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S.
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
Liquidia will report its first quarter 2025 financial results on Thursday, May 8, 2025.
Regeneron ( REGN ) Lags Q1 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of -2.49% and 7.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma ( URGN ) Moves 14.1% Higher: Will This Strength Last?
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
phaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and Innovation
Liquidia, Pulmovant, and Gossamer Bio Partner with Nonprofit to Showcase Cutting-Edge Clinical Trials and Breakthrough Therapies
UPDATE - Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Liquidia ( NASDAQ:LQDA )
MORRISVILLE, N.C., April 01, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation LQDA, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company's business at a fireside chat at ...
UPDATE - Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ ( treprostinil ) Inhalation Powder - Liquidia ( NASDAQ:LQDA )
MORRISVILLE, N.C., March 28, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation LQDA, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S.
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ ( treprostinil ) Inhalation Powder
The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Bloom Energy ( NYSE:BE ) , Alumis ( NASDAQ:ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut Tesla, Inc. TSLA price target from $500 to $450.
Liquidia Technologies, Inc. ( LQDA ) Reports Q4 Loss, Lags Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -21.05% and 43.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024.
Castle Biosciences, Inc. ( CSTL ) Surpasses Q4 Earnings and Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 190.91% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
BOSTON, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S.
Liquidia Technologies ( LQDA ) Moves 5.7% Higher: Will This Strength Last?
Liquidia Technologies (LQDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Does Liquidia Technologies ( LQDA ) Have the Potential to Rally 132.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 126.13% Upside in Liquidia Technologies ( LQDA ) : Can the Stock Really Move This High?
The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Technologies, Inc. ( LQDA ) Reports Q3 Loss, Tops Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.
Bolt Biotherapeutics, Inc. ( BOLT ) Reports Q3 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -11.11% and 12.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
